Patent No. 6,875,738 associated with the use of its anti-cancer substance, CTCE-9908, in the treating inhibition and cancer of angiogenesis. CTCE-9908 is made to block CXCR4, a receptor found on the surface area of cancer cells. CTCE-9908 inhibits the spread and growth of particular common cancers, with the potential for use with existing therapies to boost treatment outcomes. The patent entitled Therapeutic Chemokine Receptor Antagonists , with a term lasting to August 2019, covers a few of the methods by which CTCE-9908 treats malignancy. It strengthens the Company’s growing proprietary position in peptide-centered therapies which seek to address unmet medical requirements in cancer, cardiovascular and infectious diseases.We have become pleased to be considered a QTDP grant recipient, and become recognized by the U.S. Michael H. Tardugno, Celsion’s President and Chief Executive Officer. Investing in the biopharma industry is vital to our economy. .
The University University London research, published in the most recent online edition of Cerebral Cortex, can help in the rehabilitation of individuals whose motor abilities are broken by stroke, and shows that sportsmen and dancers could continue steadily to train even though they are physically injured mentally. In the UCL research, dancers from the Royal Ballet and specialists in capoeira – a Brazilian fighting techinques type – were asked to view video clips of ballet and capoeira actions getting performed while their mind activity was measured in a MRI scanner.